Menopause Hormone Therapy: What the Debate Gets Wrong

The story of menopausal hormone therapy is, at its core, a story about what happens when a single large study reshapes medical practice overnight — and what it costs women when that overreaction isn't corrected fast enough.

For much of the 1990s, hormone therapy was widely prescribed. Then in 2002, a major American trial called the Women's Health Initiative (WHI) released early results suggesting that combined hormone therapy raised the risk of breast cancer and heart disease. Prescriptions collapsed. Millions of women stopped treatment mid-course. Fear took over.

What followed was two decades of scientific re-examination, and the picture that emerged was considerably more nuanced. In clinical practice, this is often missed because doctors received the panic-version of the 2002 findings and — understandably — never got the same headline-level correction.

What Actually Happened With the 2002 Study

The WHI trial had real problems that took years to surface. The average participant was 63 years old — well past the menopause transition. Many already had established cardiovascular risk factors. The hormone formulation used (oral conjugated equine oestrogen combined with medroxyprogesterone acetate) is not the same as the bioidentical or body-identical hormones now commonly prescribed.

Younger women — those in their 40s or early 50s who start therapy close to the menopause — show a very different risk profile. This is what researchers now call the "timing hypothesis" or the "window of opportunity." Starting hormone therapy within ten years of the final menstrual period, or before age 60, appears to carry meaningfully lower cardiovascular risk and may even offer a protective effect on the heart.

If you're trying to make sense of these risk calculations and want to speak to a specialist, finding a gynaecologist near you is a reasonable first step. A consultation with an endocrinologist can also be valuable when thyroid or metabolic conditions overlap with menopausal symptoms.

The Real Symptoms That Go Undertreated

Hot flushes are the symptom most people associate with menopause, but they're far from the only one. Sleep disruption, joint pain, mood changes, vaginal dryness, brain fog, and recurrent urinary tract infections are all common — and often inadequately addressed.

The severity varies enormously between women. Some sail through perimenopause with minimal disruption. Others describe it as derailing their careers, their relationships, and their sense of self. For those in the severe category, undertreated symptoms carry their own health risks: chronic sleep deprivation, for instance, is not benign.

Women dealing with mental health symptoms during this transition often find the hormonal dimension of their mood changes goes unacknowledged. Consulting a mental health specialist alongside a gynaecologist can make a substantial difference in how these years are managed.

Bone health is another area that quietly suffers. Oestrogen plays a direct role in maintaining bone density, and the years following menopause are when osteoporosis — a condition that causes bones to become fragile — most commonly develops. Many women don't find out until a fracture happens. An orthopaedic consultation can assess bone health risk long before it becomes critical.

The Breast Cancer Question

This is the part of the debate that is legitimately complicated, and it's where honest writing requires honesty about uncertainty.

The evidence on breast cancer risk with combined hormone therapy (oestrogen plus progestogen) does suggest a small elevated risk with prolonged use — though the absolute numbers are much smaller than the original headlines implied. Oestrogen-only therapy, used by women who have had a hysterectomy (surgical removal of the uterus), does not appear to carry the same increased breast cancer risk and may even be associated with a reduced risk in some studies.

The type of progestogen used matters. Synthetic progestogens like medroxyprogesterone acetate appear to carry a different risk profile than micronised progesterone — a body-identical form increasingly prescribed in many countries. This distinction is not always communicated clearly to patients, which is a gap in practice that needs to change.

If you have a personal or family history of breast cancer, speaking with an oncologist before making any decision about hormone therapy is essential. Risk-benefit conversations need to be individual, not population-level.

Who Is Hormone Therapy Actually For?

Current guidelines from major endocrinology and gynaecology bodies suggest that for healthy women under 60 who are within ten years of menopause onset and who have moderate to severe symptoms, the benefits of MHT generally outweigh the risks. This is not a fringe position — it represents the evolving consensus of the past fifteen years of re-analysis.

Women with premature ovarian insufficiency (POI) — where the ovaries stop functioning before age 40 — have an especially clear case for hormone therapy. Without it, they face significantly elevated risks of cardiovascular disease, osteoporosis, and cognitive decline. For these women, treatment isn't optional in any meaningful sense; it's preventive care.

The picture is different for women who have certain hormone-sensitive cancers, uncontrolled blood pressure, or a history of blood clots. A cardiologist's assessment is warranted if cardiovascular risk is a concern before starting therapy.

Routes of Administration: This Detail Matters

Most of the elevated stroke and blood clot risk associated with older hormone studies relates to oral (tablet) oestrogen. When oestrogen is delivered through the skin — via patches, gels, or sprays — it bypasses the liver's first-pass processing, and current evidence suggests the clot risk is substantially lower or absent.

This is a practical, important detail that many women never hear. The delivery method isn't just a matter of convenience; it changes the risk calculation. Transdermal (through-the-skin) oestrogen is now the preferred route for most women, particularly those with cardiovascular concerns.

Discussing these options thoroughly with a women's health specialist or a gynaecologist experienced in menopause management is strongly recommended before starting any regimen.

What About "Natural" Alternatives?

Many women, nervous about conventional hormone therapy, turn to phytoestrogens (plant-based oestrogen-like compounds found in soy and some supplements), black cohosh, or other complementary approaches. The evidence for most of these is modest at best.

Some women do find relief from mild symptoms with dietary changes, nutritional support, and physiotherapy for joint and pelvic floor symptoms. These are reasonable additions — not replacements — for women with significant hormonal symptoms.

Ayurvedic approaches are also sought by many women in India. Consulting a qualified Ayurveda practitioner alongside a conventional doctor allows for an integrated approach, though it's worth being clear-eyed about what the evidence does and doesn't support.

The Conversation Most Doctors Aren't Having

A recurring theme in women's health is that menopause doesn't always receive the attention it deserves in a standard 10-minute clinical encounter. Symptoms get attributed to stress, ageing, or depression. Hormone levels go unchecked. Women are sent away with antidepressants when the underlying driver is oestrogen deficiency.

This isn't a criticism of individual doctors — it reflects a systemic gap in how menopause has historically been taught and prioritised. But it means patients need to advocate for themselves. Ask specifically about hormone levels. Ask about the difference between oral and transdermal oestrogen. Ask what your individual risk profile looks like.

If you're not getting those answers, it may be worth seeking out a specialist doctor with a specific interest in women's hormonal health, or booking an appointment at a hospital with a dedicated women's health department.

For women in Kolkata, finding a gynaecologist in the city through a platform like Doctar allows you to compare profiles, read patient reviews, and book appointments without the usual delays.